1. Coresh J., Astor B. C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003; 41 (1):1–12.
2. McClellan W. M., Resnick B., Lei L., et al. Prevalence and severity of chronic kidney disease and anemia in the nursing home population. J Am Med Dir Assoc. 2010; 11 (1):33–41.
3. Collins A. J., Foley R. N., Herzog C., et al. United States Renal Data System 2008 Annual Data Report. Am J Kidney Dis. 2009; 53 (1 Suppl):1–374.
4. Forman D. E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004; 43 (1):61–7.
5. Parfrey P. S., Foley R. N. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999; 10 (7):1606–15.
6. Smirnov A. V., Shilov E. M., Dobronravov V. A. et al. National Guidelines. Chronic Kidney disease: the main precipices of screening, diagnostics, prevention, treatment. Klinicheskaja nefrologija 2012; 4:4–43. Russian (Смирнов А. В., Шилов Е. М., Добронравов В. А. и соавт. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Клиническая нефрология 2012; 4:4–43).
7. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013; 3:1–150.
8. Matsuo S., Imai E., Horio M., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53 (6):982 92.
9. Go A. S., Chertow G. M., Fan D., et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351 (13):1296 305.
10. Glynn L. G., Reddan D., Newell J., et al. Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant 2007; 22 (9):2586 94.
11. Levey A. S., de Jong P. E., Coresh J., et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2010; http:/www.kidney-international.org.
12. Functional state of kidney and cardiovascular risk prognosis. Russian Guidelines. Cardiovascular Therapy and Prevention 2008; 7 (6). Suppl. 3. Russian (Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Российские рекомендации. Кардиоваскулярная терапия и профилактика 2008; 7 (6). Приложение 3).
13. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013; 31:1281–357.
14. Bakris G. L., Mangrum A., Copley J. B., et al. Effect of Calcium Channel or –Blockade on the Progression of Diabetic Nephropathy in African Americans. Hypertension 1997; 29:744–50.
15. Robles N. R. Calcium Antagonists and renal failure: new properties for new generations. Med Hypotheses Res 2006; 3:709–25.
16. Ruggenenti P., Fassi A., Ilieva A. P., et al.: for the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing Microalbuminuria in Type 2 Diabetes. N Engl J Med 2004; 351 (19):1941–51.
17. Berkels R., Taubert D., Bartels H., et al. Amlodipine increases endothelial nitric oxide by dualmechanismus. Pharmacology 2004; 70:39–45.
18. Cominacini L., Pasini A. F., Pastorino A. M., et al. Comparative effects of different dihydropyridines on the expression of adhessionmolecules induced by TNF-alpha on endothelial cells. JHypertens 1999;17:1837–41.
19. Cominacini L., Garbin U., Fratta Pacini A., et al. Lacidipine inhibits the activation of the transcription factor NF-kappaB and the expression of adhesion molecules induced by pro-oxidant signals on endothelial cells. J Hypertens 1997; 15:1633–40.
20. Dalla Vestra M., Pozza G., Mosca A., et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 2004; 17 (5):259–66.
21. Robles N. R., Ocon J., Gomez C. F., et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail. 2005; 27 (1):73–80.
22. Sabbatini M., Leonardi A., Testa R., et al. Effect of Calcium Antagonists on Glomerular Arterioles in Spontaneously Hypertensive Rats. Hypertension 2000; 35:775–9.
23. Barrios V., Navarro A., Esteras A., et al. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Press 2002; 11 (2):95–100.
24. Barrios V., Escobar C., de la Figuera M., et al. Tolerability of high doses of lercanidipine versus high doses of other dihydrohypidine in daily clinical practice. The TOLERANCE. Cardiovascr Ther 2008; 26:2–9.
25. Schaeffner E. S., Kurth T., Curhan G. C., et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14:2084 91.
26. Diagnostics and correction of lipid disorders with the purpose of prophylaxis and treatment of atherosclerosis. Russian Guidelines. V revision. Russ J Cardiol, 2012; 4 (96), Suppl.1; 1–32. Russian (Диагностика и коррекция нарушений липидного обмена с целью
27. профилактики и лечения атеросклероза. Российские рекомендации, V пересмотр. Российский кардиологический журнал 2012; 4 (96):1–32).
28. ESC/EAS guidelines for the management of dyslipidaemias. European Heart Journal 2011; 32 (14):1769–818.
